Midatech Pharma plc focuses on the research and development of oncology and rare disease products in the United Kingdom, rest of Europe, and internationally. The company is developing MTX110, a direct delivery treatment for diffuse intrinsic pontine glioma, medulloblastomas, and glioblastoma multiforme; MTX114, an immuno-suppressant for topical application in psoriasis; and MTD211 and MTD219 for central nervous system and transplant anti-rejection indications. It also offers drug delivery platforms, such as Q-Sphera, a polymer microsphere microtechnology used for sustained release drug delivery; MidaSolve, an oligosaccharide nanotechnology used to solubilize drugs so that they can be administered in liquid form directly and locally into tumors; and MidaCore, a gold nanoparticle used for targeting sites of disease by using chemotherapeutic agents or immunotherapeutic agents. The company was founded in 2000 and is headquartered in Cardiff, the United Kingdom.
IPO Year:
Exchange: NASDAQ
Website: midatechpharma.com
| Date | Price Target | Rating | Analyst |
|---|
Proposed Share Consolidation, Authority to Allot Shares, Disapplication of Pre-Emption Rights, Change of Name, Adoption of New Articles and Cancellation of Admission to Trading on AIMABINGDON, OXFORDSHIRE / ACCESSWIRE / March 8, 2023 / Midatech Pharma PLC (AIM:MTPH.L)(NASDAQ:MTP), a drug delivery technology company focused on improving the bio-delivery and bio-distribution of medicines, announces, further to the Company's announcements of 9 February and 15 February 2023, that a circular (the "Circular") and formal Notice of General Meeting was posted to shareholders yesterday and will be made available on the Company's website at: www.midatechpharma.com/investors/shareholder-information.The
ABINGDON, UK / ACCESSWIRE / March 8, 2022 / Midatech Pharma PLC ((AIM:MTPH, NASDAQ:MTP), a drug delivery technology company focused on improving the bio-delivery and biodistribution of medicine, is pleased to announce the appointment of Strand Hanson Limited as the Company's Nominated and Financial Adviser with immediate effect.Turner Pope Investments (TPI) Ltd will be the Company's sole broker.For further information, please contact:Midatech Pharma PLCStephen Stamp, CEO, CFOTel: +44 (0) 29 2048 0180www.midatechpharma.com Strand Hanson Limited (Nominated and Financial Adviser)James Dance / Matthew Chandler / Rob PatrickTel: +44 (0)20 7409 3494 Turner Pope Investments (TPI) Ltd (Broker)Andre
Midatech Pharma PLC ('Midatech' or the 'Company') Midatech Strengthens Management Team with Appointment of Dr. Dmitry Zamoryakhin as Chief Scientific OfficerABINGDON, OXFORDSHIRE / ACCESSWIRE / July 12, 2021 / Midatech Pharma PLC ((AIM:MTPH, NASDAQ:MTP), a drug delivery technology company focused on improving the bio-delivery and biodistribution of medicines, announces the appointment of Dr. Dmitry Zamoryakhin as Chief Scientific Officer, a non-board role, with immediate effect.Dr. Zamoryakhin has broad experience across all phases of development of drugs and medical devices, working with regulatory authorities including the EMA, FDA, PMDA, and NMPA. Most recently, he was Chief Medical Offic
6-K - Biodexa Pharmaceuticals Plc (0001643918) (Filer)
6-K - Biodexa Pharmaceuticals Plc (0001643918) (Filer)
424B3 - Biodexa Pharmaceuticals Plc (0001643918) (Filer)
424B3 - Biodexa Pharmaceuticals Plc (0001643918) (Filer)
424B3 - Biodexa Pharmaceuticals Plc (0001643918) (Filer)
6-K - Biodexa Pharmaceuticals Plc (0001643918) (Filer)
424B4 - Biodexa Pharmaceuticals Plc (0001643918) (Filer)
EFFECT - Biodexa Pharmaceuticals Plc (0001643918) (Filer)
F-1/A - Biodexa Pharmaceuticals Plc (0001643918) (Filer)
424B3 - Biodexa Pharmaceuticals Plc (0001643918) (Filer)
SC 13G/A - Biodexa Pharmaceuticals Plc (0001643918) (Subject)
SC 13G/A - Biodexa Pharmaceuticals Plc (0001643918) (Subject)
SC 13G/A - Biodexa Pharmaceuticals Plc (0001643918) (Subject)
SC 13G/A - Biodexa Pharmaceuticals Plc (0001643918) (Subject)
SC 13G - Biodexa Pharmaceuticals Plc (0001643918) (Subject)
SC 13G - Biodexa Pharmaceuticals Plc (0001643918) (Subject)
SC 13G - Biodexa Pharmaceuticals Plc (0001643918) (Subject)
SC 13G - Midatech Pharma Plc (0001643918) (Subject)
SC 13G - Midatech Pharma Plc (0001643918) (Subject)
ABINGDON, OXFORDSHIRE / ACCESSWIRE / March 27, 2023 / Midatech Pharma PLC (AIM:MTPH.L)(NASDAQ:MTP), a drug delivery technology company focused on improving the bio-delivery and bio-distribution of medicines, is pleased to announce a new research programme coded MTD217 focusing on developing new therapeutic options for metastatic cancers with high unmet needs.BackgroundMany cancers exhibit high levels of metabolic plasticity, i.e. the ability to switch between energy-generating pathways in response to cellular stresses[1], such as those caused by chemotherapy. Highly proliferative cancers frequently use the aerobic glycolysis pathway, known as "the Warburg effect", to generate energy2. Oxidat
Share Consolidation, Change of Name, Adoption of New Articles and Cancellation of Admission to Trading on AIMABINGDON, OXFORDSHIRE / ACCESSWIRE / March 24, 2023 / Midatech Pharma PLC (AIM:MTPH)(NASDAQ:MTP), a drug delivery technology company focused on improving the bio-delivery and biodistribution of medicines, is pleased to announce that at the general meeting of the Company held earlier today (the "General Meeting"), all resolutions put to the Company's shareholders ("Shareholders") were duly passed.The full text of, inter alia, the resolutions proposed and passed at the General Meeting can be found in the Company's Shareholder Circular and Notice of General Meeting (the "Circular") which
Midatech Pharma PLC ("Midatech" or the "Company") Further re: Notice of General Meeting - Correction of Typographical ErrorsABINGDON, OXFORDSHIRE / ACCESSWIRE / March 10, 2023 / Further to the announcement made on 8 March 2023 providing notice of a general meeting (the "GM") of the Company to be held on 24 March 2023, and the publication and despatch of a circular to shareholders containing notice of the resolutions to be considered at the GM (the "Notice") and form of proxy (the "Form of Proxy"), the Company announces the following corrections to certain typographical errors identified within the Notice and Form of Proxy:· Resolution 4 of the Notice ("Resolution 4") refers to a proposed aut
Proposed Share Consolidation, Authority to Allot Shares, Disapplication of Pre-Emption Rights, Change of Name, Adoption of New Articles and Cancellation of Admission to Trading on AIMABINGDON, OXFORDSHIRE / ACCESSWIRE / March 8, 2023 / Midatech Pharma PLC (AIM:MTPH.L)(NASDAQ:MTP), a drug delivery technology company focused on improving the bio-delivery and bio-distribution of medicines, announces, further to the Company's announcements of 9 February and 15 February 2023, that a circular (the "Circular") and formal Notice of General Meeting was posted to shareholders yesterday and will be made available on the Company's website at: www.midatechpharma.com/investors/shareholder-information.The
ABINGDON, UK / ACCESSWIRE / February 15, 2023 / Midatech Pharma PLC (AIM:MTPH.L)(NASDAQ:MTP), a drug delivery technology company focused on improving the bio-delivery and bio-distribution of medicines, announces the closing of the Private Placement of 10,344,822 Units initially at an issue price of US$0.58 per Unit (further details of which were set out in the announcement of 9 February 2023).Each such Unit comprises either (i) one American Depository Share ("ADS"), one A Warrant and one and one-half B Warrants, or (ii) one Pre-Funded Warrant, one A Warrant and one and one-half B Warrants. The Company will therefore issue, in aggregate, 2,600,160 new ADSs (representing 65,004,000 new ordinar
THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN (THE "ANNOUNCEMENT") IS RESTRICTED AND IS NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO CANADA, AUSTRALIA, JAPAN OR THE REPUBLIC OF SOUTH AFRICA OR IN ANY OTHER JURISDICTION IN WHICH OFFERS OR SALES OF SECURITIES WOULD BE PROHIBITED BY APPLICABLE LAW.THIS ANNOUNCEMENT DOES NOT CONSTITUTE OR CONTAIN ANY INVITATION, SOLICITATION, RECOMMENDATION, OFFER OR ADVICE TO ANY PERSON TO SUBSCRIBE FOR OR OTHERWISE ACQUIRE ANY SECURITIES OF THE COMPANY.THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUE INSIDE INFORMATION AS STIPULATED UNDER ARTICLE 7 OF THE M
ABINGDON, OXFORDSHIRE / ACCESSWIRE / February 3, 2023 / Midatech Pharma PLC (AIM:MTPH.L)(NASDAQ:MTP), a drug delivery technology company focused on improving the bio-delivery and biodistribution of medicines, announces that it received written notification (the "Notification Letter") from The NASDAQ Stock Market LLC ("NASDAQ"), dated 31 January 2023, stating that the Company is not in compliance with the minimum bid price requirement set forth in NASDAQ's rules for continued listing on The NASDAQ Capital Market. NASDAQ Listing Rule 5550(a)(2) requires listed securities to maintain a minimum bid price of $1.00 per share, and Listing Rule 5810(c)(3)(A) provides that a failure to meet the minim
Result of General MeetingAppointment of Specialist Business Advisory Firm - QuantumaABINGDON, OXFORDSHIRE / ACCESSWIRE / January 23, 2023 / Midatech Pharma PLC (AIM:MTPH.L)(NASDAQ:MTP), a drug delivery technology company focused on improving the bio-delivery and biodistribution of medicines, announces that at its General Meeting held at 10.00 a.m. today all ordinary resolutions were carried, but all other resolutions were not passed by shareholders, as set out in the table below. As certain resolutions were inter-conditional, only Resolution 4 (general authority to allot securities) was therefore passed. Accordingly, the proposed acquisition of Bioasis Technologies, Inc. and the proposed tra
Planned Dose Escalation in Phase 1 Study of MTX-110 (MAGIC-G1 Study) in Patients with Recurrent GlioblastomaABINGDON, UK / ACCESSWIRE / January 12, 2023 / Midatech Pharma PLC (AIM:MTPH.L)(NASDAQ:MTP), an R&D biotechnology company focused on improving the bio-delivery and biodistribution of medicines, is pleased to announce that following completion of one month of treatment with MTX-110 in the first patient, its Phase I study of MTX-110 in recurrent glioblastoma ("rGB") (NCT 05324501) will continue with a planned dose escalation following a positive recommendation from the study's Data Safety Monitoring Board ("DSMB").The Phase I study, the MAGIC-G1 study, is an open-label, dose escalation s
NEW HAVEN, Conn., Jan. 11, 2023 (GLOBE NEWSWIRE) -- BIOASIS TECHNOLOGIES INC. (OTCQB:BIOAF, TSX.V:BTI))) (the "Company" or "Bioasis"), a multi-asset rare and orphan disease biopharmaceutical company developing clinical stage programs based on epidermal growth factor and a differentiated, proprietary xB3 ™ platform for delivering therapeutics across the blood-brain barrier ("BBB") and the treatment of central nervous system ("CNS") disorders in areas of high unmet medical need, today announced that it has mailed the management information circular (the "Circular") and related materials for the annual and special meeting (the "Meeting") of Bioasis securityholders to approve the previously an
Gainers electroCore (NASDAQ:ECOR) shares increased by 27.9% to $5.47 during Friday's regular session. As of 13:30 EST, electroCore's stock is trading at a volume of 91.3K, which is 434.3% of its average full-day volume over the last 100 days. The company's market cap stands at $25.9 million. Concord Medical Services (NYSE:CCM) shares rose 22.72% to $1.35. The company's market cap stands at $58.6 million. Vicarious Surgical (NYSE:RBOT) stock moved upwards by 20.03% to $1.8. As of 13:30 EST, this security is trading at a volume of 1.4 million shares, making up 378.4% of its average full-day volume over the last 100 days. The company's market cap stands at $226.7 million. Virios Therapeutic
On Friday, 469 companies hit new 52-week lows. Noteworthy Points From Today's 52-Week Lows: The largest company by market cap to set a new 52-week low was Bank of America (NYSE:BAC). TC BioPharm (Holdings) (NASDAQ:TCBP) was the smallest firm by market cap to set a new 52-week low. Silvergate Capital (NYSE:SI) made the largest move down on the session, with shares plummeting 74.5% to reach its 52-week low. BlackRock TCP Cap (NASDAQ:TCPC) saw the biggest bounce back on, as shares traded up 0.0% to rebound after it hit its new 52-week low. On Friday, the following stocks hit new 52-week lows: Bank of America (NYSE:BAC) stock hit a yearly low of $26.32. The stock was down 2.21% fo
- SEC Filing
Gainers Assure Hldgs (NASDAQ:IONM) shares moved upwards by 17.1% to $4.39 during Friday's pre-market session. The company's market cap stands at $4.8 million. Dermata Therapeutics (NASDAQ:DRMA) shares increased by 16.68% to $1.96. The company's market cap stands at $1.6 million. Impel Pharmaceuticals (NASDAQ:IMPL) shares rose 12.97% to $1.48. The market value of their outstanding shares is at $35.1 million. The company's, Q4 earnings came out today. Molecular Templates (NASDAQ:MTEM) shares moved upwards by 11.31% to $0.37. The market value of their outstanding shares is at $20.8 million. Vivani Medical (NASDAQ:VANI) stock rose 10.89% to $1.12. The company's market cap stands at $56.8 mi
Gainers VistaGen Therapeutics (NASDAQ:VTGN) shares rose 37.6% to $0.18 during Wednesday's pre-market session. The market value of their outstanding shares is at $40.3 million. 89bio (NASDAQ:ETNB) shares moved upwards by 33.85% to $14.63. The market value of their outstanding shares is at $764.1 million. Midatech Pharma (NASDAQ:MTP) shares moved upwards by 17.83% to $0.42. The company's market cap stands at $2.9 million. Lyell Immunopharma (NASDAQ:LYEL) stock increased by 17.2% to $2.58. The company's market cap stands at $643.6 million. Telesis Bio (NASDAQ:TBIO) stock moved upwards by 15.83% to $2.56. The market value of their outstanding shares is at $75.5 million. As per the news, the
Gainers TScan Therapeutics (NASDAQ:TCRX) shares increased by 28.8% to $3.4 during Tuesday's after-market session. The company's market cap stands at $82.3 million. The company's, Q4 earnings came out 4 days ago. TC BioPharm (Holdings) (NASDAQ:TCBP) shares moved upwards by 27.77% to $3.91. The market value of their outstanding shares is at $3.1 million. Nymox Pharmaceutical (NASDAQ:NYMX) shares moved upwards by 21.13% to $0.4. The market value of their outstanding shares is at $36.2 million. Virpax Pharmaceuticals (NASDAQ:VRPX) shares rose 19.44% to $0.94. The company's market cap stands at $11.0 million. Jounce Therapeutics (NASDAQ:JNCE) shares rose 18.86% to $1.26. Today's trading volu
Gainers Kimball International, Inc. (NASDAQ:KBAL) shares jumped 84.9% to $12.40 after HNI Corporation announced it will acquire the company for $485 million. Fresh Tracks Therapeutics, Inc. (NASDAQ:FRTX) rose 40.9% to $2.48 after the company announced, in its Phase 1 study, FRTX-02 was generally safe and well tolerated within the potential therapeutic dose range, meeting the study's primary objectives. Arlo Technologies, Inc. (NYSE:ARLO) gained 38% to $4.95 after the company reported better-than-expected Q4 results and issued FY23 adjusted EPS guidance above estimates. Diversey Holdings, Ltd. (NASDAQ:DSEY) gained 37.3% to $8.16 after the company announced it will be acquired by Solenis
Gainers LifeStance Health Gr (NASDAQ:LFST) stock increased by 27.2% to $6.03 during Wednesday's regular session. As of 12:30 EST, this security is trading at a volume of 2.7 million shares, making up 683.1% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $2.2 billion. As per the news, the Q4 earnings report came out today. Mesoblast (NASDAQ:MESO) shares moved upwards by 25.74% to $3.81. Trading volume for this security as of 12:30 EST is 649.6K, which is 453.9% of its average full-day volume over the last 100 days. The company's market cap stands at $561.2 million. Immuneering (NASDAQ:IMRX) shares moved upwards by 21.96% to $6.72.
Gainers Lucira Health (NASDAQ:LHDX) stock increased by 65.1% to $0.23 during Friday's after-market session. This security traded at a volume of 15.2 million shares come close, making up 248.3% of its average volume over the last 100 days. The company's market cap stands at $9.3 million. Lixte Biotech Hldgs (NASDAQ:LIXT) shares increased by 11.95% to $0.94. The market value of their outstanding shares is at $15.6 million. T2 Biosystems (NASDAQ:TTOO) shares increased by 6.3% to $0.6. The company's market cap stands at $9.7 million. Biofrontera (NASDAQ:BFRI) stock increased by 5.27% to $0.79. The company's market cap stands at $21.0 million. Aspira Womens Health (NASDAQ:AWH) stock rose 5.0